Barhl1 Inhibitors represent a class of chemical compounds designed to modulate the activity of the Barhl1 protein, which is a transcription factor involved in the regulation of gene expression during embryonic development, particularly in neural differentiation processes. These inhibitors are developed to specifically target the Barhl1 protein and interfere with its transcriptional activity. The objective of such inhibitors is to gain insights into the molecular mechanisms through which Barhl1 functions and to explore its roles in various developmental processes.
The development of Barhl1 inhibitors is rooted in the broader field of molecular biology and developmental biology, aiming to understand the intricate regulatory networks that govern neural development. These inhibitors are designed to selectively bind to Barhl1 and alter its interaction with DNA or other proteins, thereby affecting the expression of downstream target genes. Researchers utilize these inhibitors as tools for experimental purposes, dissecting the precise functions of Barhl1 in the context of embryogenesis and neural differentiation. By inhibiting Barhl1 activity, scientists can investigate the effects on neural cell fate determination and the molecular pathways influenced by this transcription factor, contributing to a deeper understanding of the complex processes that underlie embryonic development. It's important to note that Barhl1 inhibitors are primarily used as research reagents and are valuable for advancing our knowledge of gene regulation and neural development.
SEE ALSO...
Items 11 to 20 of 24 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Selectively inhibits JAK1 and JAK2 kinases, useful in myeloproliferative disorders. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A inhibits protein transport from the endoplasmic reticulum to the Golgi apparatus, disrupting cellular homeostasis and down-regulating Barhl1 expression. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
Targets the anti-apoptotic protein Bcl-2 in chronic lymphocytic leukemia. | ||||||
1-β-D-Arabinofuranosylcytosine | 147-94-4 | sc-201628 sc-201628A sc-201628B sc-201628C sc-201628D | 1 g 5 g 25 g 100 g 250 g | $147.00 $258.00 $508.00 $717.00 $1432.00 | 1 | |
1-β-D-Arabinofuranosylcytosine inhibits DNA polymerase, leading to DNA damage and activation of DNA damage response pathways, ultimately suppressing Barhl1 expression. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Inhibits various tyrosine kinases, including BCR-ABL and SRC, for leukemia. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D inhibits RNA polymerase, preventing transcription of mRNA and leading to reduced levels of Barhl1 transcripts. | ||||||
Allopurinol | 315-30-0 | sc-207272 | 25 g | $128.00 | ||
Allopurinol inhibits xanthine oxidase, reducing the production of reactive oxygen species (ROS) and downstream oxidative stress responses that suppress Barhl1 expression. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Inhibits cyclin-dependent kinases (CDK4 and CDK6), used in combination for breast cancer therapy. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Targets multiple receptor tyrosine kinases (VEGFR, PDGFR, KIT) in cancer. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A inhibits histone deacetylases (HDACs), leading to histone hyperacetylation and alterations in chromatin structure that down-regulate Barhl1 expression. | ||||||